ZVRA: Zevra Therapeutics Inc. Stocks News on May 17, 2025

ZVRA

Simply Wall St.

a day ago

With 49% stake, Zevra Therapeutics, Inc. (NASDAQ:ZVRA) seems to have captured institutional investors' interest

ZVRA

Thomson Reuters StreetEvents

2 days ago

Q1 2025 Zevra Therapeutics Inc Earnings Call

ZVRA

GuruFocus.com

3 days ago

Zevra Therapeutics Inc (ZVRA) Q1 2025 Earnings Call Highlights: Navigating Growth and Challenges

ZVRA

Zacks

3 days ago

Zevra Therapeutics (ZVRA) Reports Q1 Loss, Tops Revenue Estimates

ZVRA

MT Newswires

3 days ago

Zevra Therapeutics Q1 Net Loss Narrows, Revenue Rises; Shares Gain After Hours

ZVRA

Associated Press Finance

3 days ago

Zevra Therapeutics: Q1 Earnings Snapshot

Zevra Reports First Quarter 2025 Financial Results and Corporate Update

ZVRA

GlobeNewswire

3 days ago

Zevra Reports First Quarter 2025 Financial Results and Corporate Update

ZVRA

GuruFocus.com

5 days ago

Zevra Therapeutics Inc (ZVRA) Q1 2025 Earnings Report Preview: What To Expect

Zevra Therapeutics Announces Details for Q1 2025 Financial Results Call

ZVRA

GlobeNewswire

11 days ago

Zevra Therapeutics Announces Details for Q1 2025 Financial Results Call

Zevra Therapeutics to Participate in the Citizens Life Science Conference

ZVRA

GlobeNewswire

15 days ago

Zevra Therapeutics to Participate in the Citizens Life Science Conference

Zevra Files Definitive Proxy Statement and Mails Letter to Stockholders

ZVRA

GlobeNewswire

a month ago

Zevra Files Definitive Proxy Statement and Mails Letter to Stockholders

Zevra Announces Publication of MIPLYFFA® Mechanism of Action Manuscript in Molecular Genetics and Metabolism

ZVRA

GlobeNewswire

a month ago

Zevra Announces Publication of MIPLYFFA® Mechanism of Action Manuscript in Molecular Genetics and Metabolism

ZVRA

MT Newswires

a month ago

Zevra Therapeutics Nets $150 Million From US FDA Voucher Sale, Increases Cash Reserves

Zevra Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million

ZVRA

GlobeNewswire

a month ago

Zevra Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million

ZVRA

MT Newswires

2 months ago

Zevra Therapeutics Asks Shareholders to Reject Director Nominees by Activist Investor

Zevra Therapeutics Files Preliminary Proxy

ZVRA

GlobeNewswire

2 months ago

Zevra Therapeutics Files Preliminary Proxy

Zevra Therapeutics Independent Director Acquires 33% More Stock

ZVRA

Simply Wall St.

2 months ago

Zevra Therapeutics Independent Director Acquires 33% More Stock

Zevra Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

ZVRA

Simply Wall St.

2 months ago

Zevra Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

ZVRA

MT Newswires

2 months ago

Sector Update: Health Care Stocks Decline Wednesday Afternoon

ZVRA

Thomson Reuters StreetEvents

2 months ago

Q4 2024 Zevra Therapeutics Inc Earnings Call

ZVRA

GuruFocus.com

2 months ago

Zevra Therapeutics Inc (ZVRA) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic ...

ZVRA

Zacks

2 months ago

Zevra Therapeutics (ZVRA) Reports Q4 Loss, Tops Revenue Estimates

ZVRA

Associated Press Finance

2 months ago

Zevra Therapeutics: Q4 Earnings Snapshot

ZVRA

MT Newswires

2 months ago

Zevra Therapeutics Q4 Net Loss Widens, Revenue Decreases; Shares Fall After Hours

Zevra Reports Full Year 2024 and Fourth Quarter Financial Results

ZVRA

GlobeNewswire

2 months ago

Zevra Reports Full Year 2024 and Fourth Quarter Financial Results

ZVRA

Simply Wall St.

2 months ago

Investing in Zevra Therapeutics (NASDAQ:ZVRA) five years ago would have delivered you a 83% gain

Zevra Launches New Disease State Awareness Campaign, ‘Learn NPC, Read Between the Signs,’ to Drive Early Recognition and Treatment of Niemann-Pick Disease Type C

ZVRA

GlobeNewswire

3 months ago

Zevra Launches New Disease State Awareness Campaign, ‘Learn NPC, Read Between the Signs,’ to Drive Early Recognition and Treatment of Niemann-Pick Disease Type C

Praxis hits trial setback; Bristol Myers lays off staff in New Jersey

ZVRA

BioPharma Dive

3 months ago

Praxis hits trial setback; Bristol Myers lays off staff in New Jersey

Zevra sells priority review voucher for $150m to support drug launches

ZVRA

Pharmaceutical Technology

3 months ago

Zevra sells priority review voucher for $150m to support drug launches

ZVRA

MT Newswires

3 months ago

Zevra Therapeutics to Sell Priority Review Voucher for $150 Million

Zevra Therapeutics Enters Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million

ZVRA

GlobeNewswire

3 months ago

Zevra Therapeutics Enters Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million

Zevra to Report 2024 Fourth Quarter and Full Year Financial Results

ZVRA

GlobeNewswire

3 months ago

Zevra to Report 2024 Fourth Quarter and Full Year Financial Results

Zevra to Participate at Upcoming Investor Conferences

ZVRA

GlobeNewswire

3 months ago

Zevra to Participate at Upcoming Investor Conferences

ZVRA

MT Newswires

3 months ago

Zevra Therapeutics Insider Sold Shares Worth $727,390, According to a Recent SEC Filing

Zevra Therapeutics to Present at the 21st Annual WORLDSymposium™

ZVRA

GlobeNewswire

4 months ago

Zevra Therapeutics to Present at the 21st Annual WORLDSymposium™

Zevra Therapeutics to Participate at Upcoming Investor Conferences

ZVRA

GlobeNewswire

4 months ago

Zevra Therapeutics to Participate at Upcoming Investor Conferences

Positive Signs As Multiple Insiders Buy Zevra Therapeutics Stock

ZVRA

Simply Wall St.

4 months ago

Positive Signs As Multiple Insiders Buy Zevra Therapeutics Stock

ZVRA

Simply Wall St.

5 months ago

Analysts Expect Breakeven For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Before Long

ZVRA

MT Newswires

5 months ago

Zevra Therapeutics to Join Nasdaq Biotechnology Index

Zevra Therapeutics to be Added to Nasdaq Biotechnology Index (Nasdaq: NBI) Effective December 23, 2024

ZVRA

GlobeNewswire

5 months ago

Zevra Therapeutics to be Added to Nasdaq Biotechnology Index (Nasdaq: NBI) Effective December 23, 2024

A drug for fewer than 1,000 patients? Awareness and diagnosis are key.

ZVRA

Pharma Voice

5 months ago

A drug for fewer than 1,000 patients? Awareness and diagnosis are key.

Zevra Therapeutics Announces Organizational Changes

ZVRA

GlobeNewswire

5 months ago

Zevra Therapeutics Announces Organizational Changes

ZVRA

Simply Wall St.

5 months ago

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) has caught the attention of institutional investors who hold a sizeable 42% stake

ZVRA

GlobeNewswire

6 months ago

Zevra Therapeutics to Participate at Upcoming Investor Conferences

Zevra Therapeutics Launches MIPLYFFA for Niemann-Pick Disease

ZVRA

TipRanks

6 months ago

Zevra Therapeutics Launches MIPLYFFA for Niemann-Pick Disease

Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA™ (arimoclomol) for Treatment of Niemann-Pick Disease Type C

ZVRA

GlobeNewswire

6 months ago

Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA™ (arimoclomol) for Treatment of Niemann-Pick Disease Type C

ZVRA

Simply Wall St.

6 months ago

Analysts Have Made A Financial Statement On Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Third-Quarter Report

Zevra Therapeutics Third Quarter 2024 Earnings: Misses Expectations

ZVRA

Simply Wall St.

6 months ago

Zevra Therapeutics Third Quarter 2024 Earnings: Misses Expectations

ZVRA

GuruFocus.com

6 months ago

Zevra Therapeutics Inc (ZVRA) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ...

ZVRA

Zacks

6 months ago

Zevra Therapeutics (ZVRA) Reports Q3 Loss, Lags Revenue Estimates

ZVRA

Associated Press Finance

6 months ago

Zevra Therapeutics: Q3 Earnings Snapshot

Zevra Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Updates

ZVRA

GlobeNewswire

6 months ago

Zevra Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Updates

Assertio (ASRT) Reports Q3 Loss, Lags Revenue Estimates

ZVRA

Zacks

6 months ago

Assertio (ASRT) Reports Q3 Loss, Lags Revenue Estimates

Zevra Therapeutics to Present Data Demonstrating Relevance of Swallow Domain in Niemann-Pick Disease Type C Clinical Severity Scale at 53rd Child Neurology Society Annual Meeting

ZVRA

GlobeNewswire

6 months ago

Zevra Therapeutics to Present Data Demonstrating Relevance of Swallow Domain in Niemann-Pick Disease Type C Clinical Severity Scale at 53rd Child Neurology Society Annual Meeting

ZVRA

GuruFocus.com

6 months ago

Zevra Therapeutics Inc (ZVRA) Q3 2024: Everything You Need To Know Ahead Of Earnings

Zevra Therapeutics to Participate at the Guggenheim Securities Healthcare Innovation Conference on Wed, Nov. 13

ZVRA

GlobeNewswire

6 months ago

Zevra Therapeutics to Participate at the Guggenheim Securities Healthcare Innovation Conference on Wed, Nov. 13

Zevra Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Nov. 12, 2024

ZVRA

GlobeNewswire

7 months ago

Zevra Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Nov. 12, 2024

Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

ZVRA

Zacks

7 months ago

Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

ZVRA

Zacks

7 months ago

Earnings Preview: Zevra Therapeutics (ZVRA) Q3 Earnings Expected to Decline

Zevra Therapeutics to Participate in Rare Disease Panel at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC

ZVRA

GlobeNewswire

7 months ago

Zevra Therapeutics to Participate in Rare Disease Panel at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC

ZVRA

GuruFocus.com

7 months ago

Zevra Therapeutics Inc (ZVRA) Q2 2024 Earnings Call Highlights: Strategic Advancements Amid ...

NUCDF and Zevra Therapeutics Launch Check Ammonia Campaign to Highlight Critical Importance of Prompt, Accurate Blood Ammonia Testing for Diagnosing Urea Cycle Disorders

ZVRA

GlobeNewswire

7 months ago

NUCDF and Zevra Therapeutics Launch Check Ammonia Campaign to Highlight Critical Importance of Prompt, Accurate Blood Ammonia Testing for Diagnosing Urea Cycle Disorders

ZVRA

MT Newswires

7 months ago

Guggenheim Initiates Zevra Therapeutics With Buy Rating, $20 Price Target

Zevra Stock Surges Close to 70% in 3 Months: Here's Why

ZVRA

Zacks

7 months ago

Zevra Stock Surges Close to 70% in 3 Months: Here's Why

ZVRA

Zacks

8 months ago

Biotech Stock Roundup: BHVN, WVE, ZVRA Stocks Up on Updates, BIIB & UCBs Study Data & More

ZVRA

Simply Wall St.

8 months ago

Investors in Zevra Therapeutics (NASDAQ:ZVRA) have seen decent returns of 67% over the past year

ZVRA

Zacks

8 months ago

Zevra Therapeutics (ZVRA) Moves 9.1% Higher: Will This Strength Last?

Zevra Therapeutics to Present Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at Sleep Europe 2024

ZVRA

GlobeNewswire

8 months ago

Zevra Therapeutics to Present Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at Sleep Europe 2024

ZVRA

MT Newswires

8 months ago

JMP Securities Initiates Zevra Therapeutics at Outperform

FDA approves Zevra Therapeutics’ Miplyffa for Niemann-Pick disease

ZVRA

Pharmaceutical Technology

8 months ago

FDA approves Zevra Therapeutics’ Miplyffa for Niemann-Pick disease

Zevra Therapeutics' Drug Becomes First FDA-Approved Treatment For Ultra-Rare Neurodegenerative Disease

ZVRA

Benzinga

8 months ago

Zevra Therapeutics' Drug Becomes First FDA-Approved Treatment For Ultra-Rare Neurodegenerative Disease

Zevra Therapeutics’ MIPLYFFA™ (arimoclomol) Receives U.S. FDA Approval as Treatment for Niemann-Pick Disease Type C

ZVRA

GlobeNewswire

8 months ago

Zevra Therapeutics’ MIPLYFFA™ (arimoclomol) Receives U.S. FDA Approval as Treatment for Niemann-Pick Disease Type C

ZVRA

MT Newswires

8 months ago

Zevra Therapeutics Gets US FDA Approval For Miplyffa

Zevra Therapeutics Presented New Data for Arimoclomol and OLPRUVA® (Sodium Phenylbutyrate) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium

ZVRA

GlobeNewswire

8 months ago

Zevra Therapeutics Presented New Data for Arimoclomol and OLPRUVA® (Sodium Phenylbutyrate) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium

ZVRA

GlobeNewswire

9 months ago

Zevra Therapeutics to Participate at Upcoming Investor Conferences

ZVRA

Simply Wall St.

9 months ago

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Just Reported And Analysts Have Been Cutting Their Estimates

ZVRA

MT Newswires

9 months ago

Zevra Therapeutics Q2 Net Loss Widens, Revenue Slumps

ZVRA

Zacks

9 months ago

Zevra Therapeutics (ZVRA) Reports Q2 Loss, Tops Revenue Estimates

ZVRA

Associated Press Finance

9 months ago

Zevra Therapeutics: Q2 Earnings Snapshot

Zevra Therapeutics Reports Second Quarter 2024 Financial Results and Corporate Highlights

ZVRA

GlobeNewswire

9 months ago

Zevra Therapeutics Reports Second Quarter 2024 Financial Results and Corporate Highlights

ZVRA

MT Newswires

9 months ago

Zevra Therapeutics Prices $60 Million Stock Offering

Zevra Therapeutics Announces Pricing of Underwritten Offering of Common Stock

ZVRA

GlobeNewswire

9 months ago

Zevra Therapeutics Announces Pricing of Underwritten Offering of Common Stock

Zevra Therapeutics Announces Proposed Public Offering of Common Stock

ZVRA

GlobeNewswire

9 months ago

Zevra Therapeutics Announces Proposed Public Offering of Common Stock

Zevra Therapeutics to Present at Canaccord Genuity’s 44th Annual Growth Conference

ZVRA

GlobeNewswire

9 months ago

Zevra Therapeutics to Present at Canaccord Genuity’s 44th Annual Growth Conference

ZVRA

Zacks

9 months ago

Earnings Preview: Zevra Therapeutics (ZVRA) Q2 Earnings Expected to Decline

ZVRA

MT Newswires

9 months ago

Top Midday Gainers

Zevra wins FDA panel backing for previously rejected arimoclomol

ZVRA

Pharmaceutical Technology

9 months ago

Zevra wins FDA panel backing for previously rejected arimoclomol

FDA Advisory Committee Votes Favorably that the Data Support Arimoclomol as Effective Treatment for Patients with Niemann-Pick Disease Type C

ZVRA

GlobeNewswire

9 months ago

FDA Advisory Committee Votes Favorably that the Data Support Arimoclomol as Effective Treatment for Patients with Niemann-Pick Disease Type C

Zevra Therapeutics to Report Second Quarter 2024 Financial Results

ZVRA

GlobeNewswire

10 months ago

Zevra Therapeutics to Report Second Quarter 2024 Financial Results

Zevra Therapeutics Insider Confidence Rewarded, Stock Hits US$235m Market Cap

ZVRA

Simply Wall St.

10 months ago

Zevra Therapeutics Insider Confidence Rewarded, Stock Hits US$235m Market Cap

ZVRA

Zacks

10 months ago

Zevra (ZVRA) Rises on Update on Niemann-Pick Disease Type C Drug

ZVRA

Zacks

10 months ago

Zevra Therapeutics (ZVRA) Surges 21.9%: Is This an Indication of Further Gains?

AbbVie names new R&D head; Arcutis eczema cream approved

ZVRA

BioPharma Dive

10 months ago

AbbVie names new R&D head; Arcutis eczema cream approved

FDA Convenes Expert Panel Meeting For Zevra Therapeutics' Arimoclomol, Analyst Optimistic About Approval Despite Small Patient Base

ZVRA

Benzinga

10 months ago

FDA Convenes Expert Panel Meeting For Zevra Therapeutics' Arimoclomol, Analyst Optimistic About Approval Despite Small Patient Base

Zevra Announces FDA Advisory Committee Meeting to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C

ZVRA

GlobeNewswire

10 months ago

Zevra Announces FDA Advisory Committee Meeting to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C

Zevra Therapeutics Expands Executive Leadership Team

ZVRA

GlobeNewswire

a year ago

Zevra Therapeutics Expands Executive Leadership Team

ZVRA

Simply Wall St.

a year ago

Breakeven On The Horizon For Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

Zevra Therapeutics Transitions to Orsini as the Specialty Pharmacy Provider for OLPRUVA® (sodium phenylbutyrate), a Treatment for Certain Urea Cycle Disorders

ZVRA

GlobeNewswire

a year ago

Zevra Therapeutics Transitions to Orsini as the Specialty Pharmacy Provider for OLPRUVA® (sodium phenylbutyrate), a Treatment for Certain Urea Cycle Disorders

ZVRA

MT Newswires

a year ago

Zevra Therapeutics Files $350 Million Mixed-Shelf; Shares Fall After Hours

Zevra Therapeutics Announces Positive Final Results from Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at SLEEP 2024 Annual Meeting

ZVRA

GlobeNewswire

a year ago

Latest Zevra Therapeutics Inc. (ZVRA) News on May 17, 2025

Share on Social Networks: